We’re excited to announce that SHINE submitted a Drug Master File with the FDA for non-carrier-added lutetium-177 (Lu-177) chloride, a radiopharmaceutical at the forefront of precision cancer treatment.

In targeted cancer therapy, the cancer-killing radioisotope Lu-177 is paired with a cancer-seeking molecule to form a smart compound that directly targets and attacks cancer cells.

Read more about this important step in ensuring the world has scalable access to these game-changing, cancer-destroying products. SHINE On!

Read the Press Release